Skip to Content

XL184 20mg (Cometriq 20 mg)

Generic Name: cabozantinib

Pill with imprint XL184 20mg is Gray, Capsule-shape and has been identified as Cometriq 20 mg. It is supplied by Exelixis, Inc..

Cometriq is used in the treatment of thyroid cancer and belongs to the drug classes multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Cometriq 20 mg is not a controlled substance under the Controlled Substance Act (CSA).

Images for XL184 20mg

Cometriq

Generic Name:
cabozantinib
Imprint:
XL184 20mg
Strength:
20 mg
Color:
Gray
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Multikinase inhibitors
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Exelixis, Inc.
National Drug Code (NDC):
42388-0014

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide